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Abstract
Background: Multiple osteochondroma (MO) is an autosomal dominant skeletal disorder characterized by the
formation of multiple osteochondromas, and exostosin-1 (EXT1) and exostosin-2 (EXT2) are major causative genes in
MO. In this study, we evaluated the genetic backgrounds and mutational patterns in Japanese families with MO.
Results: We evaluated 112 patients in 71 families with MO. Genomic DNA was isolated from peripheral blood
leucocytes. The exons and exon/intron junctions of EXT1 and EXT2 were directly sequenced after PCR amplification.
Fifty-two mutations in 47 families with MO in either EXT1 or EXT2, and 42.3 % (22/52) of mutations were novel
mutations. Twenty-nine families (40.8 %) had mutations in EXT1, and 15 families (21.1 %) had mutations in EXT2.
Interestingly, three families (4.2 %) had mutations in both EXT1 and EXT2. Twenty-four families (33.8 %) did not
exhibit mutations in either EXT1 or EXT2. With regard to the types of mutations identified, 59.6 % of mutations were
inactivating mutations, and 38.5 % of mutations were missense mutations.
Conclusions: We found that the prevalence of EXT1 mutations was greater than that of EXT2 mutations in
Japanese MO families. Additionally, we identified 22 novel EXT1 and EXT2 mutations in this Japanese MO cohort.
This study represents the variety of genotype in MO.
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Background
Multiple osteochondromas (MO) is a relatively rare
autosomal dominant skeletal disorder characterized by
the formation of multiple osteochondromas and skeletal
deformities, including limb length discrepancy, bowing
deformities of the forearms, valgus deformity of the
lower extremities, and scoliosis [1–3]. In Western coun-
tries, the prevalence of MO in the general population is
one in every 50,000 individuals, and men tend to be
affected more frequently than women [4, 5]. Osteochon-
droma is a benign bone tumor exhibiting cartilage-
capped bone growth that typically originates from the
metaphysis of long bones or surface of flat bones.
Patients commonly feel pain or irritation of the tissues
due to osteochondroma, and some patients may undergo
multiple surgeries during their life in an attempt to
relieve the symptoms of this disorder [6]. Malignant
transformation of osteochondroma toward chondrosar-
coma is a serious complication in MO and occurs in
0.38–7.0 % of patients [6–9].
The exostosin-1 (EXT1) and exostosin-2 (EXT2) genes,
which encode heparin sulfate glycosyltransferases, are
major causative genes in MO [10, 11]. EXT1 is located
on chromosome 8q23-q24 [12], and EXT2 is located on
chromosome 11p11-p12 [13]; these genes are essential
for heparan sulfate chain elongation. Approximately
90 % of patients with MO harbor EXT1 or EXT2 germ-
line mutations; however, the genetic background of
patients with MO is heterogeneous. Several reports have
described mutational variations and novel mutations in
EXT1 and EXT2 genes in patients with MO in several
different countries [14–17], and the distribution of
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mutations in the EXT1 and EXT2 genes has been shown
to vary. For example, in Spanish patients with MO, 74 %
had mutations in EXT1, and 21 % had mutations in
EXT2 [14]. In contrast, in Polish patients with MO,
54.6 % had mutations in EXT1 and 30.3 % had muta-
tions in EXT2 [15]. Most of these mutations are inacti-
vating mutations, including nonsense, frameshift, and
splice-site mutations [18]. However, only one study has
described variations in genotypes for Japanese patients
with MO [16].
Therefore, in this study, we sought to determine gen-
etic backgrounds and mutational patterns in 71 Japanese
families with MO; this report describes the genetic diag-
nostic results of the largest Japanese cohort of MO pa-
tients presented to date and identified several novel
mutations in the EXT1 and EXT2 genes in MO.
Results
Identification of 22 novel genetic lesions
In this study, all exons and intron/exon junctions in
EXT1 and EXT2 were sequenced in 112 patients with
MO from 71 families. Eighty (71.4 %) patients harbored
52 mutations in either EXT1 or EXT2. All EXT1 and
EXT2 mutations are shown in Table 1. Twenty-nine
families (40.8 %) had mutations in EXT1, and 15 families
(21.1 %) had mutations in EXT2. Interestingly, three
families (4.2 %) had mutations in both EXT1 and EXT2.
Twenty-four families (33.8 %) did not have mutations in
EXT1 or EXT2. The distribution of mutations was as fol-
lows: 40.4 % (21/52) of patients had missense mutations,
30.8 % (16/52) of patients had frameshift mutations,
21.2 % (11/52) of patients had nonsense mutations,
5.8 % (3/52) of patients had splicing mutations, and
1.9 % (1/52) of patients had insertions. Of all 52 muta-
tions, 22 mutations (42.3 %) were novel mutations that
had not been registered in the Multiple Osteochondroma
Mutation Database (MOdb) (http://medgen.ua.ac.be/
LOVDv.2.0/home.php) [18]. Of these mutations, 17 muta-
tions (77.3 %) were identified in the EXT1 gene, while five
mutations (22.7 %) were found in the EXT2 gene. The dis-
tribution of novel mutations was as follows: 27.3 % (6/22)
of patients had missense mutations, 31.8 % (7/22) of pa-
tients had frameshift mutations, 22.7 % (5/22) of patients
had nonsense mutations, 9.1 % (2/22) of patients had spli-
cing mutations, and 4.5 % (1/22) of patients had
insertions.
Characteristic genome mutations in five families with MO
Interestingly, five families with MO showed unique ge-
notypes (MO-11, -25, -44, -47, and -59) as illustrated in
Fig. 1. In the family with MO-11, one MO patient har-
bored missense mutations in both exon 2 of EXT1 and
exon 2 of EXT2. Moreover, parents and children in the
families with MO-25, -44, and -47 showed different
genotypes. In the family with MO-59, a patient had a
double missense mutation in EXT1.
Discussion
In this study, we evaluated the presence and features of
EXT1 and EXT2 mutations in Japanese families with
MO. Our data demonstrated that 29 families (40.8 %)
had mutations in EXT1, and 15 families (21.1 %) had
mutations in EXT2. Moreover, three families (4.2 %) had
mutations in both EXT1 and EXT2, and 24 families
(33.8 %) did not have mutations in either EXT1 or
EXT2. Of the 52 mutations observed in this study, 34
mutations were identified in EXT1, and 18 mutations
were identified in EXT2. Of the 52 mutations 22 novel
mutations were identified. Thus, the data presented
herein provides important insights into the genetic
causes of MO in Japanese families.
MO is an autosomal dominant disorder, and germline
and heterozygous mutations conferring loss of function in
the EXT1 and EXT2 genes are main causes of MO. Muta-
tional variations in EXT1 and EXT2 are continuously be-
ing reported; as of January 2015, 432 mutations in EXT1
and 223 mutations in EXT2 were registered in the MOdb
(http://medgen.ua.ac.be/LOVDv.2.0/home.php) [18]. Sev-
eral studies have described the mutational variations in
EXT1 and EXT2 in European countries and Asia. For ex-
ample, in Spanish patients with MO, 74 % were found to
have mutations in EXT1, and 21 % were found to have
mutations in EXT2 [14]. Additionally, in Polish patients
with MO, 54.6 and 30.3 % were found to have mutations
in EXT1 and EXT2, respectively [15]. In an Italian cohort,
69 % of patients were found to have mutations in EXT1,
and 27 % of patients were found to have mutations in
EXT2. In a previous study of Japanese families with MO,
17 (40 %) of the 23 families had a mutation in EXT1, and
six (14 %) of the 23 families had a mutation in EXT2 [16].
In contrast, in Chinese families with MO, 13.9 and 33.3 %
of the 36 families were found to have mutations in EXT1
and EXT2, respectively [17]. In most studies, the preva-
lence of EXT1 mutations has been reported to be higher
than that of EXT2 mutations. Similarly, in our current
analysis, a greater proportion of EXT1 mutations was ob-
served (EXT1: 40.8 %, EXT2: 21.1 %). However, mutations
in these genes were not identified in 24 families (33.8 %)
with MO; this percentage was relatively high compared
with that in European countries, where the proportion of
patients without mutations in EXT1 and EXT2 has been
shown to range from 4 to 24 % (Fig. 2a) [9, 14, 19, 20].
Further studies are needed to examine this finding such as
MLPA assays because the families with MO harboring no
mutations in this study might include deletion mutation.
While the EXT family also includes three EXT-like genes
(i.e., EXTL1, EXTL2, and EXTL3) [21–23], no reports have
described the presence of gene mutations in these three
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Table 1 Ext1 and Ext2 mutations in Japanese MO families









MO-1 4 EXT2 Exon6 Missense p.C339F c.1016G > T R F
MO-2 4 EXT1 Exon6 Frame shift p.T488fs c.1462AΔ1nt N F
MO-3 3 EXT1 Exon6 Frame shift p.T490fs c.1469TΔ1nt R F
MO-4 2 EXT1 Exon8 Frame shift p.F550fs c.T1650Δ1nt N F
MO-5 1 a- - - - - - F
MO-6 1 EXT1 Exon5 Frame shift p.R433fs c.A1297Δ2nt R F
MO-7 1 EXT2 Exon 5 Missense p.R297H c.890G > A N F
MO-8 2 EXT1 Exon1 Nonsense p.Q27X c.79C > T N F
MO-9 2 - - - - - - F
MO-10 1 - - - - - - F
MO-11 1 EXT1 Exon2 Missense p.R341S c.1023G > C R F
EXT2 Exon2 Missense p.R128W c.382C > T R F
MO-12 2 - - - - - - F
MO-13 1 EXT2 Exon8 Nonsense p.W429X c.1286G > A R F
MO-14 1 EXT1 Exon6 Frame shift p.L490fs c.1469TΔ1nt R F
MO-15 1 - - - - - - F
MO-16 1 EXT2 Exon3 Nonsense p.R182X c.544C > T R F
MO-17 2 - - - - - - F
MO-18 1 - - - - - - F
MO-19 1 - - - - - - S
MO-20 1 EXT2 Exon5 Insertion p.V282ins c.846A insertion N S
MO-21 2 EXT1 Exon2 Missense p.R340H c.1019G > A R F
MO-22 1 - - - - - - F
MO-23 2 - - - - - - F
MO-24 1 EXT2 Exon5 Missense p.R299H c.896G > A R F
MO-25 1 EXT1 Exon5 Frame shift p.P466fs c.1395del del. R F
EXT1 Exon8 Missense p.F550S c.1649T > C N F
MO-26 2 - - - - - - F
MO-27 1 EXT2 Exon2 Frame shift p.F30fs c.88TΔ5nt N F
MO-28 1 EXT1 Exon2 Missense p.R340L c.1019G > T R F
MO-29 2 EXT1 Exon3 Missense p.C355Y c.1064G > A N F
MO-30 1 - - - - - - F
MO-31 2 EXT1 Exon1 Nonsense p.W304X c.912G > A R F
MO-32 3 EXT1 Exon9 Nonsense p.W612X c.1797G > A R F
MO-33 2 EXT1 Exon1 Frame shift p.L26fs c.78 T (Δ1nt) N F
MO-34 2 - - - - - - F
MO-35 1 EXT2 Intron7 Splicing mutation - c.(1173 + 1)G > A R F
MO-36 1 EXT2 Exon3 Nonsense p.R182X c.544C > T R F
MO-37 2 EXT1 Exon1 Nonsense p.Q165X c.493C > T R F
MO-38 1 - - - - - - F
MO-39 1 - - - - - - S
MO-40 1 EXT1 Exon2 Missense p.R340H c.1019G > A R F
MO-41 2 - - - - - - F
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EXT-like genes in families with MO. Therefore, further
studies are needed to determine whether these three genes
may be causative genes in families with MO who do not
harbor mutations in EXT1 and EXT2 genes.
In MO, the most common mutation types in the EXT1
and EXT2 genes are inactivating mutations, such as
frameshift, nonsense, and splice-site mutations [24]. Simi-
larly, in data reported in MOdb from 2009, approximately
80 % of mutations in EXT1 and 77 % of mutations in
EXT2 were found to be inactivating mutations (EXT1:
frameshift 44 %, nonsense 24 %, splice-site 11 %; EXT2:
frameshift 42 %, nonsense 22 %, splice-site 13 %) [18]. In
Spanish patients with MO, the prevalence of inactivation
mutations was reported to be 79.5 % [14]. In our study, 52
mutations were found in EXT1 and EXT2, and 59.6 % (31/
52) of these mutations were inactivating mutations (with
30.8, 23.1, and 5.8 % of mutations being frameshift, non-
sense, and splice-site mutations, respectively). The propor-
tion of missense mutation was approximately 38.5 %,
which was relatively higher in this study than in previous
reports (Fig. 2b) [14, 18]. The differences in gene muta-
tions between patients with MO in Japan and other
Table 1 Ext1 and Ext2 mutations in Japanese MO families (Continued)
MO-43 2 EXT1 Exon2 Missense p.R341S c.1023G > C R F
MO-44 2 EXT2 Exon3 Missense p.A202V c.605C > T R F
EXT1 Exon1 Nonsense p.G24X c.70G > T N F
MO-45 4 EXT1 Exon1 Frame shift p.R314fs c.941G (+2nt) N F
MO-46 1 EXT1 Exon1 Nonsense p.E74X c.220G > T N F
MO-47 1 EXT2 Exon2 Missense p.L152R c.455T > G R F
EXT1 Exon1 Missense p.Q150R c.499A > G N F
MO-48 1 EXT1 Exon1 Frame shift p.T297fs c.888CΔ1nt N F
MO-49 4 - - - - - - F
MO-50 2 EXT2 Exon7 Nonsense p.Y374X c.1122C > A N F
MO-51 1 EXT2 Exon2 Frame shift p.S121fs c.361TΔ2nt R F
MO-52 2 EXT2 Exon4 Missense p.D227N c.679G > A R F
MO-53 1 EXT1 Exon3 Frame shift p.M359fs Δ8nt N F
MO-54 1 - - - - - - F
MO-55 1 - - - - - - F
MO-56 1 EXT1 Exon10 Nonsense p.Q685X c.2053C > T R F
MO-57 2 EXT1 Exon1 Frame shift p.K321fs c.960GΔ1nt N F
MO-58 1 EXT2 Exon6 Missense p.P341T c.1021C > A N F
MO-59 1 EXT1 Exon1 Missense p.I221V c.661A > G N F
EXT1 Exon5 Frame shift p.P466fs c.1395TΔ1nt R F
MO-60 2 EXT1 Exon2 Missense p.R340H c.1019G > A R F
MO-61 2 EXT1 Exon1 Frame shift p.K218fs Δ14nt R F
MO-65 1 - - - - - - F
MO-66 1 EXT1 Exon1 Frame shift p.K218fs Δ18nt R F
MO-67 1 - - - - - - S
MO-68 1 - - - - - - F
MO-70 1 EXT1 IVS9 Splicing mutation intron/exon10 G > A N F
MO-72 2 EXT1 Exon1 Nonsense p.E139X c.415G > T N F
MO-73 1 EXT2 Exon5 Missense p.R299H c.896G > A R F
MO-74 3 - - - - - - F
MO-75 2 EXT2 Exon4 Missense p.D227N c.679G > A R F
MO-76 1 - - - - - - F
MO-77 1 EXT1 IVS5 Splicing mutation exon5/intron G > T N F
a- indicates no mutations detected
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countries may be related to the differences in the preva-
lence rates of MO or the severity of skeletal abnormalities,
including scoliosis, in the various countries. Further stud-
ies are required to determine the phenotype-genotype re-
lationships in Japanese patients with MO.
In the present study, approximately 7.0 % (5/71) of
families with MO showed characteristic genotypes, e.g.
one patient bearing two mutations and a parent and
child bearing different mutations as shown in Fig. 1.
Especially, in MO-25, MO-44 and MO-47, there was
Fig. 1 Characteristic mutations and hereditary types in Japanese families with MO. Black mark represents patient with MO. White mark represents
healthy person. NA: DNA not available. Written informed consents to publish were obtained from each participants described in this figure before
study participation
Fig. 2 Comparison of mutation frequencies. a The proportions of EXT1 and EXT2 mutations. b The proportion of missense mutations
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one affected parent with MO and one (or two) affected
child, but genotypes of child differed from that of the
parents. It was reported that approximately 10 % of pa-
tients with MO exhibited de novo mutations [18]; thus,
the difference of genotype between parent and child in
the three families may be caused by de novo muta-
tions although this scenario may be very unlikely.
Therefore, in the future analysis, sequence or geno-
type might be necessary for the three families to re-
confirm these results.
In MO-59, there were two mutations in one MO
patient and one was a novel missense mutation. Either
mutation might obtain the possibility of it being a non-
pathogenic variant; however we evaluated only one
genome in MO-59 families, so it is unclear whether mu-
tation is a non-pathogenic variant.
This study has a limitation. In this study, we per-
formed the mutational analysis in EXT1 and EXT2 for
Japanese families with MO with using direct sequencing,
but MLPA analysis has not been performed for the fam-
ilies with MO harboring no mutations. Thus, the fam-
ilies with MO harboring gene deletions might not be
detected and unknown rate of EXT1and EXT2 mutation
potentially are high in this study. Further analysis will be
necessary, and now we are planning to perform whole-
genome sequencing with using next-generation sequen-
cing technology for the families with MO harboring no
mutations. In addition, in MO-25, MO-44 and MO-47,
re-sequence or genotype would be performed because of
unlikely hereditary form.
Conclusions
In this study, we evaluated and characterized mutations
in the EXT1 and EXT2 genes in 71 Japanese families
with MO. A total of 52 mutations in EXT1 and EXT2
were identified, with 22 of these mutations being re-
ported here for the first time. Additionally, we identified
several characteristics of gene mutations in EXT1 and
EXT2. Approximately 60 % of Japanese families with
MO had inactivating mutations in EXT1 and EXT2.
Interestingly, these results differed somewhat from those
from other countries and represented the variety of
genotype in MO. Further studies are needed to deter-
mine the reasons for these differences. This study pro-
vides important insights into our understanding of the
genetic features of MO in Japanese individuals.
Methods
Study design and ethical approval
In this study, we performed a multicenter study at Gifu
University, National Center for Child Health and Devel-
opment, and Kyusyu University. Ethics Committee of
Gifu University (Approval No. 22-221) approved all pro-
cedures, and all participants obtained written informed
consent before any research procedures. In case of the
participant under the age of 16 year old, written in-
formed consents (child assent and parental consent)
were obtained. In addition, written informed consents to
publish were obtained from all patients before study par-
ticipation, and in the case of the participant under the
age of 16 year old, written informed consents to publish
(child assent and parental consent) were obtained.
Patients and clinical studies
From April 2010 to September 2014, patients with MO
were recruited for genetic testing of the EXT1 and EXT2
genes. A total of 116 patients (51 women and 65 men)
from 74 families with MO were recruited. Clinical diag-
nosis was performed based on accurate family histories
and physical examinations of the patients, including pal-
pation tests for osteochondromas or joint deformities.
Ethics Committee of Gifu University approved all proce-
dures, and all participants obtained written informed
consents before all procedures.
Mutation analysis
Genomic DNA was isolated from peripheral blood leu-
cocytes of all patients with MO using a Wizard Genomic
DNA purification kit (Promega, Madison, WI, USA). All
exons and exon/intron junctions in the EXT1 and EXT2
genes (GenBank accession numbers NM_000127.2 and
NM_207122.1) were amplified by PCR. After confirming
amplification of the DNA fragments by agarose gel elec-
trophoresis and purifying the amplified DNA fragments
using a Wizard SV gel and PCR Clean-up System
(Promega), the amplified DNA fragments were directly
sequenced using a BigDye Terminator v1.1Cycle Se-
quencing kit (ABI). Sequence analyses were then per-
formed with an ABI PRISM 3100 Genetic Analyzer
(ABI). Mutations in EXT1 and EXT2 were evaluated by
comparing DNA sequences of normal EXT1 and EXT2
genes with the obtained sequences using Sequencher
software (Hitachi Software Engineering Co., Ltd., Tokyo,
Japan). Primer sequences are shown in Additional file 1:
Table S1. The detected mutations in EXT1 and EXT2
were examined to determine whether they had been re-
ported previously by consulting the MOdb (http://med-
gen.ua.ac.be/LOVDv.2.0/home.php) [18].
In four patients of three families (MO-62, 63, 64),
DNA sequence analysis could not be performed be-
cause EXT1 and EXT2 genes were not amplified by
polymerase chain reaction (PCR). Finally, 112 patients
of 71 MO families (48 women and 64 men), DNA se-
quence analysis was performed. All procedures were
approved by Ethics Committee of Gifu University,
and all participants obtained written informed con-
sents before all procedures.
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